NCT06890858 A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer
| NCT ID | NCT06890858 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Zhejiang Provincial People's Hospital |
| Condition | Ovarian Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-04 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 20 participants in total. It began in 2025-04 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective study investigating whether the research on Fasudil Hydrochloride in the treatment of gene-specific ovarian cancer can be applied to predict sensitivity to immunotherapy in non-small cell lung cancer (NSCLC) and other tumors. The study plans to enroll 20 patients with A/A genotype ovarian cancer for treatment evaluation.
Eligibility Criteria
Inclusion Criteria: 1. Patients voluntarily participate in the study, sign informed consent forms, and have good compliance. 2. After platinum based chemotherapy at Zhejiang Provincial People's Hospital, the efficacy evaluation showed that ovarian cancer patients who achieved disease stability (SD) or disease progression (PD) twice were treated with Fasudil in combination with the original chemotherapy regimen, and were confirmed to have the A/A genotype through genetic testing. Exclusion Criteria: * 1.Accompanied by hypotension 2. Bleeding like cerebral hemorrhage 3. Patients with abnormal liver function
Contact & Investigator
Yang Liu, M.D.
STUDY DIRECTOR
Zhejiang Provincial People's Hospital
Frequently Asked Questions
Who can join the NCT06890858 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06890858 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06890858 currently recruiting?
Yes, NCT06890858 is actively recruiting participants. Contact the research team at yangliuqq2003@163.com for enrollment information.
Where is the NCT06890858 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06890858 clinical trial?
NCT06890858 is sponsored by Zhejiang Provincial People's Hospital. The principal investigator is Yang Liu, M.D. at Zhejiang Provincial People's Hospital. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.